MSFT 447.67 -0.4691% AAPL 208.14 0.3133% NVDA 118.11 -6.684% GOOGL 179.22 -0.2282% GOOG 180.79 0.294% AMZN 185.57 -1.8564% META 498.91 0.8347% AVGO 1592.21 -4.0045% TSLA 182.58 -0.235% TSM 167.81 -3.5353% LLY 890.11 0.7048% V 276.3 0.3924% JPM 198.88 1.3143% UNH 489.98 1.5313% NVO 142.28 0.2254% WMT 68.9 1.4578% LVMUY 155.41 1.3169% XOM 114.04 2.9614% LVMHF 780.0 1.9608% MA 456.96 0.4639%

Virax Biolabs Group Limited Ordinary Shares

Healthcare US VRAX

1.29USD
-0.21(14.00%)

Last update at 2024-06-24T20:02:00Z

Day Range

1.241.45
LowHigh

52 Week Range

0.605.45
LowHigh

Fundamentals

  • Previous Close 1.50
  • Market Cap2.10M
  • Volume185364
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.08M
  • Revenue Per Share TTM0.04
  • Gross Profit TTM -0.00136M
  • Diluted EPS TTM-17.5

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31
Type yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31
Income before tax -5.45776M -1.74987M -0.67292M -0.73946M
Minority interest 0.00027M 0.04M 0.02M 0.03M
Net income -5.16703M -1.70883M -0.67963M -0.80113M
Selling general administrative 5.31M 1.29M 0.46M 0.60M
Selling and marketing expenses 0.03M 0.01M 0.06M 0.00769M
Gross profit -0.00136M 0.00000M -0.00943M 0.05M
Reconciled depreciation - - - -
Ebit -5.73276M -1.73368M -0.64454M -0.65124M
Ebitda -5.44229M -1.73443M -0.64427M -0.64877M
Depreciation and amortization 0.29M -0.00075M 0.00027M 0.00247M
Non operating income net other - - - -
Operating income -5.73276M -1.73368M -0.64454M -0.65124M
Other operating expenses 5.74M 1.73M 0.77M 0.75M
Interest expense 0.02M 0.02M 0.03M 0.09M
Tax provision - 0.00000M 0.00000M 0.00000M
Interest income - - - -
Net interest income -0.01547M -0.01544M -0.02864M -0.09069M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense -0.29074M -0.04104M 0.00671M 0.06M
Total revenue 0.00856M 0.00000M 0.12M 0.10M
Total operating expenses 5.73M 1.73M 0.64M 0.70M
Cost of revenue 0.00993M 0.00000M 0.13M 0.05M
Total other income expense net 0.27M -0.01619M -0.02838M -0.08822M
Discontinued operations - - - -
Net income from continuing ops -5.45776M -1.74987M -0.67292M -0.73946M
Net income applicable to common shares -5.45749M -1.70883M -0.65098M -0.71044M
Preferred stock and other adjustments - - - -
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31
Type yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31
Total assets 9.81M 0.05M 0.04M 0.02M
Intangible assets 0.18M - - -
Earning assets - - - -
Other current assets - 0.00600M - -
Total liab 0.91M 1.25M 0.87M 1.24M
Total stockholder equity 9.13M -0.97458M -0.65068M -1.05610M
Deferred long term liab - - - -
Other current liab 0.56M 0.40M 0.65M 1.02M
Common stock 0.00156M 0.00100M 0.00026M 0.00010M
Capital stock 0.00156M 0.00100M 0.00026M 0.00010M
Retained earnings -11.79446M -6.33697M -4.62814M -3.97716M
Other liab - - - -
Good will - - - -
Other assets - - - -
Cash 9.35M 0.02M 0.02M 0.02M
Cash and equivalents - - - -
Total current liabilities 0.91M 1.25M 0.87M 1.24M
Current deferred revenue 0.04M - - -
Net debt -9.20629M -0.02176M -0.01762M -0.02261M
Short term debt 0.15M - - -
Short long term debt 0.15M - - -
Short long term debt total 0.15M - - -
Other stockholder equity 20.92M 5.36M -0.05450M 2.92M
Property plant equipment - - - -
Total current assets 9.63M 0.05M 0.04M 0.02M
Long term investments - - - -
Net tangible assets 8.95M -0.97458M -0.65068M -1.05610M
Short term investments - - - -
Net receivables - 0.00000M 0.00093M 0.00000M
Long term debt - - - -
Inventory 0.02M 0.02M 0.02M 0.00000M
Accounts payable 0.16M 0.85M 0.22M 0.21M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income 20.92M 5.36M 4.03M 2.92M
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other - - - -
Deferred long term asset charges - - - -
Non current assets total 0.18M 0.00000M 0.00000M 0.00000M
Capital lease obligations - - - -
Long term debt total - - - -
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31
Type yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31
Investments -0.17840M - - -
Change to liabilities 0.07M 0.64M 0.08M -0.09682M
Total cashflows from investing activities -0.17840M -0.17840M -0.17840M -0.17840M
Net borrowings 0.03M 0.19M 0.18M 0.70M
Total cash from financing activities 13.69M 0.81M 0.59M 0.70M
Change to operating activities -0.27548M 0.00218M 0.00218M 0.00218M
Net income -5.45776M -1.74987M -0.67292M -0.73946M
Change in cash 9.33M 0.00413M -0.00499M -0.03997M
Begin period cash flow 0.02M 0.02M 0.02M 0.06M
End period cash flow 9.35M 0.02M 0.02M 0.02M
Total cash from operating activities -4.17977M -0.80907M -0.59019M -0.74461M
Issuance of capital stock 13.65M - - -
Depreciation - - - -
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory 0.02M 0.00012M -0.02107M -0.02107M
Change to account receivables 0.00000M 0.00093M -0.00093M -0.00093M
Sale purchase of stock - - - -
Other cashflows from financing activities 0.38M 0.81M 0.59M 0.70M
Change to netincome 1.46M 0.26M 0.00119M 0.06M
Capital expenditures 0.18M 0.00000M 0.00000M 0.00000M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital -0.18233M 0.64M 0.06M -0.09682M
Stock based compensation 1.73M 0.29M - -
Other non cash items -0.27427M 0.00605M 0.02M 0.09M
Free cash flow -4.35817M -0.80907M -0.59019M -0.74461M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
VRAX
Virax Biolabs Group Limited Ordinary Shares
-0.21 14.00% 1.29 - - 22.04 0.28 1133.86 0.46
NVO
Novo Nordisk A/S
0.32 0.23% 142.28 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S
-5.67 3.93% 138.76 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
6.24 1.33% 474.95 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc
10.75 1.02% 1063.89 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

Profile

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

Virax Biolabs Group Limited Ordinary Shares

20 North Audley Street, London, United Kingdom, W1K 6LX

Key Executives

Name Title Year Born
Mr. James Foster Chairman & CEO 1987
Mr. Jason D. Davis Chief Financial Officer 1972
Mr. Cameron Lee Shaw COO & Director 1987
Mr. Mark James Ternouth Chief Technical Officer 1968
Dr. Tomasz Evan George Chief Scientific Officer 1984
Mr. James Foster Chairman & CEO 1985
Mr. Mark James Ternouth Chief Technical Officer & Director 1968
Dr. Nigel McCracken M.Sc., Ph.D. Chief Operating Officer NA
Ms. Joel Yeung Accounting Manager NA
Mr. Clement Monteil Head of Scientific Research & Development NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).